Brief: Catalyst Biosciences gets IND approval in South Korea for subcutaneous factor IX program
28/03/2017 13:01
March 28 (Reuters) - Catalyst Biosciences Inc CBIO.O
* Catalyst Biosciences announces IND approval in South Korea
for next-generation subcutaneous factor IX program
* ISU ABXIS plans to initiate phase 1/2 proof-of-concept
study in individuals with severe hemophilia B in Q2 of 2017
Source text for Eikon: ID:nGNXNQZEDa
Further company coverage: CBIO.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on ISU ABXIS
See all newsBrief: Isu Abxis Q3 Operating Profit 562 Million Won, Up 287% From Year Earlier
Brief: Isu Abxis Q2 Operating Profit 9.4 Billion Won, Up 97% From Year Earlier
Brief: Isu Abxis Q2 Operating Profit 4.8 Billion Won, Up 5708.5% From Year Earlier
Brief: Isu Abxis Wins 10.5 Billion Won Order
Brief: Isu Abxis Q1 Operating Profit 3 Billion Won, Swings To Profit From Year Earlier